Document Detail

Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency.
MedLine Citation:
PMID:  24710993     Owner:  NLM     Status:  Publisher    
PURPOSE: The treatment of adults with GH deficiency (GHD) with human recombinant growth hormone has interindividual variability and several factors influence it. The aims of this study were : 1-to analyze the GH receptor (GHR) genotype in terms of exon 3 deletion GHR (d3-GHR) in adults with GHD; 2-to assess the effects of d3-GHR on initial IGF-I levels; 3-to evaluate whether d3-GHR and/or initial IGF-I levels were associated with adverse effects and/or treatment discontinuation.
METHODS: Forty-four adult patients with GHD were included. Demographic, clinical and biochemical characteristics were retrospectively evaluated at baseline and 6 months, 1 and 3 years after the initiation of treatment. d3-GHR was analyzed in 35 patients.
RESULTS: 37.1 % of patients were d3-GHR carriers (31.4 % heterozygous, 5.7 % homozygous). IGF-I at baseline was low in 64 % of patients and was not related to d3-GHR status. There was no association between the d3-GHR allele and baseline IGF-I (p = 0.14). Although adverse events were more frequent in the d3-GHR carriers (30.7 vs. 18.2 % in fl/fl) and in patients with normal IGF-I levels at diagnosis (43.7 vs. 17.8 % in patients with low IGF-I levels), this association was not statistically significant. d3-GHR status was not related to the incidence of adverse events (p = 0.4) or treatment discontinuation (p = 0.47). Baseline IGF-I levels were neither associated with adverse events (p = 0.08) nor treatment discontinuation (p = 0.75).
CONCLUSIONS: The d3-GHR allele was not related to baseline levels of IGF-I. Neither d3-GHR nor baseline IGF-I level was related to adverse events or treatment discontinuation.
P Andujar-Plata; E Fernandez-Rodriguez; C Quinteiro; F F Casanueva; I Bernabeu
Related Documents :
8727333 - True epineural neurolysis in morton's neuroma: a 5-year follow up.
24459683 - Povidone-iodine gel and solution as adjunct to ultrasonic debridement in nonsurgical pe...
24204113 - Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-4-8
Journal Detail:
Title:  Pituitary     Volume:  -     ISSN:  1573-7403     ISO Abbreviation:  Pituitary     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-4-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Purpura without vessel structural damage.
Next Document:  The Effect of Targeted and Tailored Patient Depression Engagement Interventions on Patient-Physician...